Fulcrum Therapeutics, Inc.
FULC
Rank in Stocks
#15081
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed... Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
Share Price
$3.72
Last synced: 2026-11-09
Market Cap
$283.83M
Change (1 day)
0.54%
Change (1 year)
-54.36%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Fulcrum Therapeutics, Inc. (FULC)
Category
Healthcare
Operating Margin for Fulcrum Therapeutics, Inc. (FULC)
Operating Margin as of November 2026 TTM: 0.00%
According to Fulcrum Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Fulcrum Therapeutics, Inc. from 2017 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | -100.00% |
| 2024 | -27.37% | -99.31% |
| 2023 | -3,945.24% | 122.29% |
| 2022 | -1,774.85% | 319.62% |
| 2021 | -422.97% | -47.89% |
| 2020 | -811.64% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Fulcrum Therapeutics, Inc.'s operating margin
What was Fulcrum Therapeutics, Inc.'s operating margin in 2025?
In 2025, Fulcrum Therapeutics, Inc.'s operating margin was 0.00%, compared with -27.37% in 2024.
How has Fulcrum Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Fulcrum Therapeutics, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2023 (-3,945.24%).
How does Fulcrum Therapeutics, Inc.'s operating margin compare with similar companies?
Fulcrum Therapeutics, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.